Physician profile
David J Obrien
NPI 1790724532
$902.29
in general payments reported to CMS, 2019-2025
16 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $316 · 2020: $68.56 · 2022: $142 · 2023: $124 · 2024: $112 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $176.64 | 2019-2025 | Eylea Hd, Eylea |
| Kls-Martin L.P. | $160.69 | 2019 | |
| Alcon Vision LLC | $92.73 | 2022-2024 | Rocklatan |
| Harrow Eye, LLC | $90.48 | 2025 | Vevye |
| Abbvie INC. | $66.91 | 2022-2023 | |
| Eyepoint US, INC. | $63.60 | 2020-2023 | |
| Allergan, INC. | $56.31 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $39.71 | 2019 | |
| Sun Pharmaceutical Industries INC. | $24.07 | 2020 | |
| Rxsight INC | $23.84 | 2022 | |
| Biotissue Holdings INC. | $22.32 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.25 | 2019 | |
| Dompe US, INC. | $18.31 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $15.38 | 2025 | Xiidra, Lotemax, Vyzulta |
| Genentech USA, INC. | $15.09 | 2025 | Vabysmo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $14.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Obrien listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.